Relative Success of pQTL− and GWAS−supported T−I Pairs

	(A[G]/S[G])/ (A![G]/S![G])		RS, 95% CI
By genetic evidence source			
pQTL	(23/46)/(757/7154)		4.73 (3.51, 6.36)
OMIM (Mendelian disease)	(79/192)/(1440/12830)		3.67 (3.07, 4.37)
Neale UKBB	(40/110)/(1479/12912)		3.17 (2.47, 4.08)
FinnGen	(26/79)/(1493/12943)		2.85 (2.08, 3.92)
Genebass (gene burden)	(14/46)/(1505/12976)		2.62 (1.69, 4.07)
GWAS catalog	(124/455)/(1395/12567)		2.46 (2.10, 2.88)
All OTG	(127/484)/(1392/12538)		2.36 (2.02, 2.77)
PICCOLO	(33/125)/(1486/12897)		2.29 (1.70, 3.08)
By L2G share only			
L2G share: >= 0.25	(147/608)/(1372/12414)		2.19 (1.88, 2.54)
L2G share: >= 0.5	(127/484)/(1392/12538)		2.36 (2.02, 2.77)
L2G share: >= 0.75	(87/297)/(1432/12725)		2.60 (2.17, 3.13)
By pQTL + L2G share			
L2G share: >= 0.25	(25/61)/(755/7139)		3.88 (2.85, 5.28)
L2G share: >= 0.5	(23/46)/(757/7154)		4.73 (3.51, 6.36)
L2G share: >= 0.75	(18/30)/(762/7170)		5.65 (4.18, 7.62)
By pQTL MR−coloc type			
Cis−MR	(20/40)/(760/7160)		4.71 (3.43, 6.47)
Trans−MR	(13/21)/(767/7179)		5.79 (4.12, 8.16)
Mixed−MR	(14/24)/(766/7176)		5.46 (3.87, 7.71)
MR+coloc	(20/36)/(760/7164)		5.24 (3.88, 7.07)
By protein platform			
pQTL: Somascan	(6/16)/(91/843)		3.47 (1.79, 6.73)
pQTL: Olink	(20/42)/(403/3259)		3.85 (2.77, 5.36)

Phase I−Launch Relative Success (RS), 95% CI